Abstract
Introduction
Type 1 diabetes (T1D) is associated with an increased risk of cardio-vascular disease (CVD) compared to people without diabetes. Although regular physical activity is encouraged as a cornerstone of good diabetes management [1, 2] , physical inactivity rates remain high [3] . Patients often cite low functional capacity and loss of metabolic control (short-term and/or long term glycaemic disturbances) as barriers to beginning or maintaining regular physical activity [4] .
Functional capacity, defined as the ability to perform aerobic work during maximal exercise testing can be assessed by means of cardio-pulmonary exercise (CPX)
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Diabetology & Metabolic Syndrome testing. This non-invasive, sensitive test provides an assessment of integrative responses of cardiovascular, pulmonary and musculoskeletal systems across a submaximal to maximal continuum and can be utilised to identify fatigue of cardiovascular or respiratory origin [5] . Most reported studies in people with T1D have assessed maximum cardio-pulmonary values such as the peak oxygen uptake (VO 2peak ) [6] [7] [8] . VO 2peak is the highest rate of oxygen that can be consumed during exercise involving the majority of muscle mass at sea-level and is defined by the Fick equation as the product of cardiac output and arteriovenous oxygen difference [5] . Achieving a true VO 2peak requires strong motivation and physical fitness, but for people with T1D with 'low exercise tolerance' the perception of exercise-induced pain may encourage premature test termination. In addition, the presence of diabetes complications such as neuropathy, nephropathy and underlying CVD may exacerbate pain or damage during exercise and reduce the validity of CPX testing in detailing accurate maximum cardio-respiratory parameters e.g. VO 2 plateau, maximum heart rate (HR max ).
Most activities in daily life are performed at low-to moderate intensity and do not require maximum cardiorespiratory effort. It may be more relevant in people with T1D to explore cardio-respiratory data obtained during sub-maximal stages of CPX testing. The rate of oxygen use at sub-maximal exercise intensities provides an indication of the economy of use of oxygen for an individual to the work rate and has been shown to predict endurance performance in healthy individuals [9] . Furthermore, identification of the sub-maximal work rate at which there is an increase in use of non-oxidative fuel sources (i.e. cellular glycolysis) results in a greater production of carbon dioxide (CO 2 ), pyruvate and lactic acid fermentation. Identification of such 'thresholds' involving ventilation, heart rate and/or blood lactate have been studied as sub-maximal predictors of endurance capacity in healthy cohorts and in people with chronic disease [5] . As an example the heart rate turn point (HRTP), which is based on findings from Conconi et al., was significantly associated with the second lactate threshold [10] [11] [12] [13] . This heart rate derived threshold is defined as the intersection of two regression lines of the heart rate to performance curve between early stages of CPX testing [peri-first lactate turn point (LTP 1 )] and maximum power output (P max ), determined from a second-degree polynomial representation satisfying the condition of least error squares [14] . However, there is a lack of information about their use in people with T1D in predicting functional capacity.
Lower maximum cardio-respiratory variables have been reported in participants with T1D compared to healthy individuals in some studies but not in others [8, 15] . A review by Baldi et al. [16] shed some light on the influence of glycaemic control within people with T1D and when compared to healthy individuals. Patients with poor glycaemic control demonstrated a lower peak functional capacity than those patients with good glycaemic control. No information currently exists on the influence of glycaemic control on sub-maximal cardio-respiratory parameters obtained from a CPX test. Such information might reveal additional insights on the impact of glycaemia on the functioning of the cardio-vascular and respiratory system and provide further support for the use of moderate intensity exercise tests that reduce stress on the patient.
The aim of this study was to examine the relationship of glycaemic control to sub-maximal and maximum cardiopulmonary markers obtained during CPX testing in people with T1D.
Materials and methods

Participant characteristics
Adults (aged 18-45 years, both inclusive) with T1D eligible for the study had a body mass index (BMI) of 18-27 kg/m 2 , glycated haemoglobin (HbA 1c ) level ≤ 9.5% (80 mmol/mol) and were performing regular physical cardiorespiratory exercise during the last 3 months before screening. Exclusion criteria included cancer, cardiac diseases, supine blood pressure outside the range 90-140 mmHg for systolic blood pressure or 50-90 mmHg for diastolic blood pressure, recurrent severe hyperglycaemia or hypoglycaemia unawareness and smoking [17] . Sixty-four people with T1D were included for analyses (Table 1) . Data were extracted from a clinical trial (NCT01704417) [17] .
Study procedures
After the assessment of eligibility, patients were asked to fill in the International Physical Activity Questionnaire (IPAQ) to assess physical activity (MET min/week). Patients characteristics, medical history and medications were documented in a case report form (CRF). Afterwards, HbA1c was measured via a venous blood sample collected from the antecubital vein (Automated Glycohemoglobin Analyzer HLC-723G8, Tosoh Europe N.V, Belgium). Immediately before and after CPX testing, venous blood was collected to analyse blood glucose concentration to ensure euglycaemia during CPX testing (Super GL Glucose Analyzer, Dr. Müller Gerätebau GmbH, Germany). If pre-exercise venous blood glucose concentration was below 4.4 mmol/l carbohydrates were given (15-30 g) and if blood glucose concentration was above 13.9 mmol/l a small bolus correction dose was administered. No hypo-(< 3.9 mmol/l) or severe hyperglycaemia (> 19.4 mmol/l) occurred before or during CPX testing. The timing of bolus insulin injection was not exactly pre-defined, but participants were told to avoid the peak action of bolus insulin during CPX testing (this means avoiding bolus insulin injections less than 120 min prior to the start of CPX testing). Participants performed a CPX test until volitional exhaustion on a cycle ergometer (Ergospirometer PowerCube ® -Ergo, Ganshorn Medizin Electronic, GER). Participants sat quietly on the cycle ergometer for 3 min (0 W) before they started the warm-up period of 3 min cycling at a workload of 30 W for females and 40 W for males. Then, the workload was increased by 30 W for females and 40 W for males every 3 min until maximum volitional exhaustion. Finally, a cool-down period was performed for 1 min.
Measurements
Pulmonary gas exchange variables were collected continuously by breath-by-breath measurement and then averaged over 10 s. VO 2peak was defined as the 1 min average in oxygen (O 2 ) consumption during the highest work rate. Heart rate and blood pressure were measured continuously via a 12-lead electrocardiogram and an automatic sphygmomanometer (Ergospirometer PowerCube ® -Ergo, Ganshorn Medizin Electronic, GER). The non-invasive anaerobic threshold was defined by the HRTP [18] . HRTP was demarcated as the intersection of two regression lines of the heart rate to performance curve between post-warm-up and maximum power output (P max ), determined from the second-degree polynomial representation satisfying the condition of least error squares [14] . Additionally, the second ventilatory threshold (VT 2 ) was determined by means of the ventilation/ carbon dioxide (VE/VCO 2 ) slope [19] to control for the accuracy of HRTP.
Statistical analysis
Data (10 s average) were expressed as absolute values and relative to maximum physiological variables and P max . Data were tested for distribution via Shapiro-Wilks normality test and non-normal distributed data were log transformed. Stepwise linear regression was used to explore relationships between glycaemic control (HbA 1c ) and CPX obtained cardio-respiratory data and performance markers with p ≤ 0.05. Data were adjusted for sex, age, BMI, blood glucose concentration at the start of CPX testing and duration of diabetes. Post hoc power analysis for the primary outcome [stepwise linear regression: dependent variable HbA 1c levels, independent variables time to exhaustion (Time max ) and oxygen economy at HRTP] resulted in a power (1-beta error probability) of 0.96.
Participants were divided into quartiles (Q) based on HbA 1c levels, and respective sub-maximal and maximal CPX derived cardio-respiratory data and performance markers were analysed by one-way analysis of variance (ANOVA) followed by a fishers least significant difference multiple comparison post hoc test (LSD). Multiple regression analysis was performed to explore relationships between changes in Time max and independent variables, VO 2peak and oxygen uptake at the heart rate turn point (VO 2HRTP ), body mass adjusted values of P max and power output at the heart rate turn point (P HRTP ) as well as oxygen economy at P max [VO 2peak /P max (ml/min/W)] and at HRTP [VO 2HRTP /P HRTP (ml/min/W)]. All statistics were performed with a standard software package of SPSS software version 22 (IBM Corporation, USA) and Prism Software version 7.0 (GraphPad, USA).
Results
Exercise performance data
Maximum physiological parameters were found at HR max of 185 ± 11 b/min, VO 2peak 37 ± 5 ml/kg/min, respiratory exchange ratio (RER) 1.22 ± 0.09 and P max 231 ± 47 W. No significant differences were found between the HRTP and the VT 2 as well as for the comparison of pre-and post-exercise blood glucose concentration as given in Table 2 .
Glycaemic control and functional capacity
As shown in Fig. 1 , sex-, age-, BMI-, blood glucose concentration at the start of CPX testing-and duration of diabetes-adjusted stepwise linear regression model revealed that HbA 1c was related to Time max and oxygen consumption at the power output elicited at the submaximal threshold of the heart rate turn point (VO 2HRTP / P HRTP ) (r = 0.47, R 2 = 0.22, p = 0.03).
Grouped HbA 1c levels and functional capacity
Grouping participants based on quartiles of glycaemic control resulted in HbA 1c levels of 6.7 ± 0.5% (49 ± 6 mmol/mol) for quartile I, 7.6 ± 0.1% (60 ± 1 mmol/mol) for quartile II, 8.0 ± 0.1% (63 ± 1 mmol/mol) for quartile III and 9.1 ± 0.6% (76 ± 7 mmol/mol) for quartile IV (p < 0.01). No significant differences were found for physical activity (p = 0.68), resting HR (p = 0.42), systolic blood pressure (p = 0.18) and diastolic blood pressure (p = 0.83) between groups.
Significant differences were found at Time max between QI vs. QIV (mean difference 2.5 ± 1.0 min, p = 0.02) and at VO 2HRTP /P HRTP between QI vs. QII (− 1.5 ± 0.6 ml/ min/W, p = 0.02) and QI vs QIV (− 1.6 ± 0.71 ml/ min/W, p = 0.01) (Fig. 2) .
White bar = QI (HbA 1c 6. ± 0.5%; 4 ± 6 mmol/ mol), bright-grey bar = QII (HbA 1c 7. ± 0.1%; 60 ± 1 mmol/mol), dark-grey bar = QIII (HbA 1c 8. ± 0.1%; 6 ± 1 mmol/mol) and black bar = QIV (HbA 1c 9.1 ± 0.6%; 7 ± 7 mmol/mol). Values are given as mean and SD. "*" represents p ≤ 0.05.
Relationships of time to exhaustion and cardio-pulmonary responses during CPX testing
Multiple regression analysis revealed that changes in VO 2peak , VO 2HRTP , P max , P HRTP , VO 2HRTP /P HRTP as well as VO 2peak /P max constitute independent predictors of Time max (r = 0.74, p < 0.01) and those variables could explain 55% of the alteration in Time max .
Discussion
This study demonstrated an important relationship between glycaemic control and the cardio-respiratory responses to CPX testing in people with T1D. Exercise economy is defined as the rate of oxygen use at a given workload. We found that individuals with poorer glycaemic control (higher HbA 1c values) displayed a higher rate of O 2 use at a sub-maximal work rate (HRTP) and earlier Time max . This result is confirmed by the findings from Tagougui et al. in which the increase in deoxyhemoglobin (reflection of relative tissue deoxygenation) in the vastus lateralis was blunted in patients with T1D and with poor glycaemic control during CPX testing [20] . Interestingly, the maximum oxygen consumption was negatively correlated with changes in deoxyhemoglobin. Our findings are in contrast to recent studies evaluating the association between glycaemic control and functional capacity [6, 8] . Stubbe et al. could not find an association between HbA 1c levels and the O 2 uptake at the anaerobic lactate threshold [8] . This contrast in comparison to our results might explained by lower and more homogeneous HbA 1c levels as observed in our cohort. The variation in glycaemic control and its upper and lower extremes clearly contributed to the association between HbA 1c levels and rates of O 2 use at the HRTP. Turinese et al. also did not find significant relationships between the glycaemic control and CPX derived markers [6] . However, the lack of associations might be originated by the low number of participants (N = 17).
There may be several postulated reasons for our findings. During exercise, skeletal muscle consumes most of the inhaled O 2 and a greater O 2 cost for a given exercise intensity might indicate fibre atrophy and/or morphological abnormalities in the mitochondria [21] . Reduced skeletal muscle mitochondrial ATP production rates have also been associated with poor glycaemic control [22] . Furthermore, the capillary density surrounding skeletal muscle has been shown to be lower in individuals with T1D [23] . A reduced oxidative capacity within prime mover muscles increases dependence on supporting muscles, and increases the overall oxygen cost of the activity for a given workload. Furthermore, an earlier limit on O 2 use within a muscle shifts energy metabolism towards non-oxidative glycolysis and an earlier lowered pH [24] . Alternatively, oxygen supply systems may be compromised more in individuals with poorer glycaemic control. Red blood cell dynamics have been shown to be altered in T1D rats [25] with velocity and flux reduced in comparison to non-diabetics, albeit with a similar haematocrit.
People with T1D may display cardiomyopathy and this seems dependent on the HbA 1c value which has been hypothesised to alter cardiac structure, e.g. increased left ventricular wall thickness and mass, and impaired diastolic function. Interestingly, poor glycaemic control was associated with reduced stroke volume and cardiac output in athletes with T1D compared with non-diabetic individuals, despite an equivalent amount of training [26] . This reduction in stroke volume might be caused by earlier diastolic dysfunction, which reduces the atrioventricular pressure gradient and causes early diastolic left ventricular filling [16] .
The decreased economy at early stages during CPX testing translated to shorter exercise test duration. Indeed, approximately 55% of the shorter total exercise time could be accounted for lowered O 2 uptake, decreased power output and less economical use of O 2 for both at the HRTP and maximum power. Taken this into account, it might be that regular exercise training, which increases these physiological parameters, might have similar potential to neutralise the negative influence of glycaemic control on functional capacity [27] and even on cardiovascular autonomic regulation [28] .
This study is limited by the heterogeneity and the wide range in the duration of diabetes, age, blood glucose concentration at the start of CPX testing and sex distribution. However, we addressed this limitation as we have adjusted for these factors. Additionally, it might be that different levels of blood glucose influenced 
Conclusions
In conclusion, in this well-characterised study, individuals with T1D and poorer glycaemic control displayed less economical use of oxygen at sub-maximal work rates and an earlier time to exhaustion during CPX testing. Nevertheless, exercise training could have the same potential to counteract the influence of poor glycaemic control on functional capacity. Abbreviations T1D: type 1 diabetes; CVD: cardio-vascular disease; CPX: cardio-pulmonary exercise; VO 2peak : peak oxygen uptake; HR max : maximum heart rate; CO 2 : carbon dioxide; HRTP: heart rate turn point; LTP 1 : first lactate turn point; P max : maximum power output; IPAQ: International Physical Activity Questionnaire; VT2: second ventilatory; VE/VCO 2 slope: ventilation/carbon dioxide slope; BMI: body mass index; HbA 1c : glycated haemoglobin; O 2 : oxygen; Q: quartiles; ANOVA: analysis of variance; LSD: fishers least significant difference multiple comparison post hoc test; Time max : time to exhaustion; VO 2HRTP : oxygen uptake at the heart rate turn point; P HRTP : power output at the heart rate turn point; RER: respiratory exchange ratio; HR HRTP : heart rate at the heart rate turn point.
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